Baseline patient characteristics
| Variable . | Decitabine (N = 21) . |
|---|---|
| Median age, y (range) | 67 (40-89) |
| Male sex, n (% of patients) | 12 (57%) |
| Performance status, n (% of patients) | |
| ECOG 0 | 8 (38%) |
| ECOG 1 | 12 (57%) |
| ECOG 2 | 1 (5%) |
| MF subtype, n (% of patients) | |
| PMF | 16 (76%) |
| Post-PV MF | 4 (19%) |
| Post-ET MF | 1 (5%) |
| Lille risk status, n (% of patients) | |
| High risk = 2 | 8 (38%) |
| Intermediate risk = 1 | 9 (43%) |
| Low risk = 0 | 4 (19%) |
| IPSS risk score, n (% of patients) | |
| High risk | 11 (52%) |
| Intermediate-2 | 5 (24%) |
| Intermediate-1 | 5 (24%) |
| Cytogenetic risk, n (% of patients) | |
| Favorable | 11 (52%) |
| Unfavorable | 7 (33%) |
| Unavailable | 3 (14%) |
| Transfusion dependence, n (% of patients) | 12 (57%) |
| Median prior lines of therapy, n (range) | 1 (0-4) |
| Median platelet count, ×109/L (range) | 96 (11-493) |
| Median Hb, g/dL (range) | 8.9 (6.4-12) |
| Median white blood cell count, ×109/L (range) | 5.7 (1.5-47.4) |
| Median absolute neutrophil count, ×109/L (range) | 3.43 (0.07-37) |
| Baseline palpable spleen, n (% of patients) | 18 (86%) |
| JAK2 V617F positive, n (% of patients) | 11 (52%) |
| Variable . | Decitabine (N = 21) . |
|---|---|
| Median age, y (range) | 67 (40-89) |
| Male sex, n (% of patients) | 12 (57%) |
| Performance status, n (% of patients) | |
| ECOG 0 | 8 (38%) |
| ECOG 1 | 12 (57%) |
| ECOG 2 | 1 (5%) |
| MF subtype, n (% of patients) | |
| PMF | 16 (76%) |
| Post-PV MF | 4 (19%) |
| Post-ET MF | 1 (5%) |
| Lille risk status, n (% of patients) | |
| High risk = 2 | 8 (38%) |
| Intermediate risk = 1 | 9 (43%) |
| Low risk = 0 | 4 (19%) |
| IPSS risk score, n (% of patients) | |
| High risk | 11 (52%) |
| Intermediate-2 | 5 (24%) |
| Intermediate-1 | 5 (24%) |
| Cytogenetic risk, n (% of patients) | |
| Favorable | 11 (52%) |
| Unfavorable | 7 (33%) |
| Unavailable | 3 (14%) |
| Transfusion dependence, n (% of patients) | 12 (57%) |
| Median prior lines of therapy, n (range) | 1 (0-4) |
| Median platelet count, ×109/L (range) | 96 (11-493) |
| Median Hb, g/dL (range) | 8.9 (6.4-12) |
| Median white blood cell count, ×109/L (range) | 5.7 (1.5-47.4) |
| Median absolute neutrophil count, ×109/L (range) | 3.43 (0.07-37) |
| Baseline palpable spleen, n (% of patients) | 18 (86%) |
| JAK2 V617F positive, n (% of patients) | 11 (52%) |
The table shows the baseline characteristics of the 21 patients enrolled on the study. The majority of patients had PMF. Approximately half of the enrolled patients had high-risk disease by IPSS risk score, and more than half of the patients were transfusion dependent at baseline; 86% had baseline splenomegaly detected by physical palpation.
ECOG, Eastern Cooperative Oncology Group; ET, essential thrombocythemia; IPSS, International Prognostic Scoring System; PV, polycythemia vera.